Multiple Myeloma

CLINICAL_TRIALS trial_result · 2025-05-11

Clinical Trial Update: A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 1]

Epizyme's Phase 1 study of EZM0414 (IPN60210) in relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma …

CLINICAL_TRIALS research · 2025-05-11

Clinical Trial Update: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy [Phase 1]

This document provides a status update for a Phase 1 clinical trial evaluating the SVN53-67/M57-KLH peptide vaccine in newly diagnosed multi…

CLINICAL_TRIALS trial_result · 2025-05-09

Clinical Trial Update: Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]

Phase 3 Japan expansion cohort update comparing Belantamab Mafodotin with Bortezomib and Dexamethasone versus Daratumumab with Bortezomib an…

CLINICAL_TRIALS research · 2025-05-09

Clinical Trial Update: Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT [Phase 2]

This Phase 2 trial is comparing autologous stem cell transplant followed by anti-BCMA CAR-T therapy versus autologous transplant alone in pa…

CLINICAL_TRIALS safety_alert · 2025-05-08

Clinical Trial Update: Corneal Findings in Patients Treated With Belantamab Mafodotin

A clinical trial update notes corneal findings in patients treated with belantamab mafodotin and indicates the associated trial was terminat…

CLINICAL_TRIALS research · 2025-05-06

Clinical Trial Update: MMRF Molecular Profiling Protocol

MMRF updates its molecular profiling protocol for multiple myeloma and plasma malignancies. The trial remains active but not recruiting.

CLINICAL_TRIALS trial_result · 2025-05-02

Clinical Trial Update: Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

Phase 2 study of magrolimab combinations in relapsed/refractory multiple myeloma was terminated; results have been posted.

CLINICAL_TRIALS trial_result · 2025-05-02

Clinical Trial Update: Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study

This completed clinical trial (NCT05053100) investigates the risk of blood clots and bleeding in patients with hematologic cancers.

CLINICAL_TRIALS trial_result · 2025-05-01

Clinical Trial Update: Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation [Phase 1, Phase 2]

A Phase 1/Phase 2 clinical trial evaluated melphalan hydrochloride in patients with newly diagnosed multiple myeloma undergoing donor stem c…

CLINICAL_TRIALS research · 2025-05-01

Clinical Trial Update: Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]

Clinical trial update for a Phase Ib study of SAR650984 in combination with carfilzomib for relapsed or refractory multiple myeloma.

CLINICAL_TRIALS research · 2025-05-01

Clinical Trial Update: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies [Phase 1, Phase 2]

IDP-121 is being studied in a Phase 1/2 trial for relapsed/refractory hematologic malignancies and is currently recruiting.

CLINICAL_TRIALS trial_result · 2025-04-30

Clinical Trial Update: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma [Phase 2]

A Phase 2 trial evaluating the combination of carfilzomib, pomalidomide, and dexamethasone in high-risk multiple myeloma; the study is curre…

CLINICAL_TRIALS research · 2025-04-30

Clinical Trial Update: GR1803 Injection in Patients With RRMM [Phase 2]

GR1803 is being studied in relapsed/refractory multiple myeloma in a Phase 2 trial, and recruitment is ongoing.

CLINICAL_TRIALS trial_result · 2025-04-29

Clinical Trial Update: Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma [NA]

A completed clinical trial evaluating an exercise program to improve quality of life in older adults with multiple myeloma.

CLINICAL_TRIALS research · 2025-04-29

Clinical Trial Update: A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation [Phase 2]

This is a Phase 2 clinical trial evaluating the combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in relapsed/refract…

CLINICAL_TRIALS research · 2025-04-27

Clinical Trial Update: GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

This clinical trial update indicates that GR1803 is being evaluated in a Phase 2 study for relapsed/refractory multiple myeloma, with recrui…

CLINICAL_TRIALS trial_result · 2025-04-25

Clinical Trial Update: Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

Phase 1 study of Descartes-11 in relapsed/refractory multiple myeloma was terminated, with results posted on 2025-04-25.

CLINICAL_TRIALS trial_result · 2025-04-25

Clinical Trial Update: A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma [Phase 1]

Phase 1 study evaluating JNJ-54767414 (HuMax CD38) in combination with backbone therapies for multiple myeloma has completed.

CLINICAL_TRIALS research · 2025-04-25

Clinical Trial Update: Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

A completed real-world study by Regeneron evaluating clinical outcomes in patients with relapsed and refractory multiple myeloma.

CLINICAL_TRIALS other · 2025-04-24

Clinical Trial Update: TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 2]

Clinical trial update indicates completion of a Phase 2 study of TJ202 with dexamethasone in relapsed or refractory multiple myeloma.

CLINICAL_TRIALS trial_result · 2025-04-24

Clinical Trial Update: Improving Patient Experience: BMBA [NA]

The BMBA clinical trial sponsored by Thomas Jefferson University has completed, but no specific results are provided in the update.

CLINICAL_TRIALS research · 2025-04-24

Clinical Trial Update: Immuno-PRISM (PRecision Intervention Smoldering Myeloma) [Phase 2]

Phase 2 Immuno-PRISM trial evaluating a precision intervention for smoldering multiple myeloma is currently recruiting.

CLINICAL_TRIALS trial_result · 2025-04-23

Clinical Trial Update: China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]

Phase 3 trial update evaluating the efficacy and safety of belantamab mafodotin with bortezomib and dexamethasone versus daratumumab with bo…

CLINICAL_TRIALS research · 2025-04-23

Clinical Trial Update: Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) [Phase 2]

This Phase 2 trial compares elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post-transplant maintenance in newly diagn…

CLINICAL_TRIALS trial_result · 2025-04-22

Clinical Trial Update: Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study [Phase 4]

A Phase 4 trial compares alternative pomalidomide dosing schedules (4 mg every other day vs 2 mg and 4 mg daily) in relapsed/refractory mult…

Top drugs studied for this disease